New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - modafinil 100mg;   - tablet - 100 mg - active: modafinil 100mg   excipient: colloidal silicon dioxide crospovidone lactose lactose monohydrate povidone purified talc sodium stearyl fumarate - · to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy. · to treat excessive sleepiness associated with moderate to severe chronic shift work sleep disorder where non pharmacological interventions are unsuccessful or inappropriate.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - levetiracetam 1000mg;   - film coated tablet - 1000 mg - active: levetiracetam 1000mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose opadry white amb 84f58775 povidone purified talc - indicated for: - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; - add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and - add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - levetiracetam 250mg;   - film coated tablet - 250 mg - active: levetiracetam 250mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose opadry blue amb 84f80803 povidone purified talc - indicated for: - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; - add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and - add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - levetiracetam 500mg;   - film coated tablet - 500 mg - active: levetiracetam 500mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose opadry yellow amb 84f82508 povidone purified talc - indicated for: - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; - add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and - add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - levetiracetam 750mg;   - film coated tablet - 750 mg - active: levetiracetam 750mg   excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch microcrystalline cellulose opadry pink amb 84f84674 povidone purified talc - indicated for: - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation; - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; - add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and - add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - ephedrine hydrochloride 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine hydrochloride 30 mg/ml excipient: water for injection - indicated in the treatment of hypotension secondary to spinal anaesthesia in adults.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - pethidine hydrochloride 50 mg/ml - solution for injection - 5% w/v - active: pethidine hydrochloride 50 mg/ml excipient: sodium hydroxide water for injection - pethidine is indicated for short-term (24-36 hours) relief of moderate to severe pain. it can be given via the following routes of administration - intramuscular, subcutaneous, slow intravenous bolus injection, intravenous infusion and patient controlled analgesia (pca).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - eimeria acervulina hp; eimeria maxima cp; eimeria maxima mfp; eimeria mitis hp; eimeria tenella hp - misc. vaccines or anti sera - eimeria acervulina hp vaccine-general active 500.0 ooc/dose; eimeria maxima cp vaccine-general active 200.0 ooc/dose; eimeria maxima mfp vaccine-general active 100.0 ooc/dose; eimeria mitis hp vaccine-general active 1000.0 ooc/dose; eimeria tenella hp vaccine-general active 500.0 ooc/dose - immunotherapy - poultry broilers (meat for human consum) | chickens | chooks | meat birds - coccidiosis - see label for causes | eimeria acervulina | eimeria arloingi | eimeria bovis | eimeria brunetti | eimeria christenseni | eimeria maxima | eimeria mitis | eimeria mivati | eimeria necatrix | eimeria ninakohlyakimovae | eimeria praecox | eimeria tenella | eimeria zuernii

European Union - English - EMA (European Medicines Agency)

linde healthcare ab - nitric oxide - hypertension, pulmonary; respiratory insufficiency - other respiratory system products - inomax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.

New Zealand - English - Medsafe (Medicines Safety Authority)

max health limited - ergometrine maleate 0.5 mg/ml; oxytocin 5 iu/ml ((8.5 µg) added as 200 iu/ml solution.) - solution for injection - active: ergometrine maleate 0.5 mg/ml oxytocin 5 iu/ml ((8.5 µg) added as 200 iu/ml solution.) excipient: carbon dioxide chlorobutanol hemihydrate glacial acetic acid maleic acid sodium acetate trihydrate sodium chloride water for injection - active management of the third stage of labour (as a means to promote separation of the placenta and to reduce blood loss).